Cargando…

Combined Ruxolitinib and Venetoclax Treatment in a Patient with a BCR-JAK2 Rearranged Myeloid Neoplasm

Hematological malignancies with a BCR-JAK2 rearrangement have been described only sporadically in the literature over the last three decades. Although most patients suffer from a chronic myeloid neoplasm with marked eosinophilia, the clinical presentation varies significantly and can even manifest a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lap, Coen J., Nassereddine, Samah, Liu, Min-Ling, Nava, Victor E., Aggarwal, Anita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8337103/ https://www.ncbi.nlm.nih.gov/pubmed/34367701 http://dx.doi.org/10.1155/2021/2348977

Ejemplares similares

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy
por: Nassereddine, Samah, et al.
Publicado: (2018)

Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib
por: Yi, Jun Ho, et al.
Publicado: (2019)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy
por: Roche, Kyle C., et al.
Publicado: (2022)

A rare cause of persistent leukocytosis with massive splenomegaly: Myeloid neoplasm with BCR-PDGFRA rearrangement—Case report and literature review
por: Gao, Lu, et al.
Publicado: (2022)

Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2022)

Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan
por: Tabassum, Najia, et al.
Publicado: (2014)

Myeloid/lymphoid neoplasm with eosinophilia and BCR/FGFR1 rearrangement with transformation to cortical T-lymphoblastic lymphoma and erythroid precursors: a case report
por: Isaza, Alejandro Pineda, et al.
Publicado: (2023)

Combined venetoclax and alvocidib in acute myeloid leukemia
por: Bogenberger, James, et al.
Publicado: (2017)

Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies
por: McKinnell, Zoe, et al.
Publicado: (2022)

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
por: Zhou, A, et al.
Publicado: (2015)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
por: Gangat, Naseema, et al.
Publicado: (2020)

Myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA presenting as myeloid sarcoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021)

Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement
por: Di Giacomo, Danika, et al.
Publicado: (2021)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
por: Griffioen, Mila S., et al.
Publicado: (2022)

Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PCM1::JAK2 with erythroblastic sarcoma: a case report and literature review
por: Zhang, Lina, et al.
Publicado: (2023)

Alternative end-joining in BCR gene rearrangements and translocations: Alternative end-joining in BCR gene rearrangements and translocations
por: Bai, Wanyu, et al.
Publicado: (2022)

Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms
por: Kim, Hye-Ran, et al.
Publicado: (2013)

Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
por: Tregnago, Claudia, et al.
Publicado: (2022)

IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2(V617F)-positive myeloproliferative neoplasms
por: de Melo Campos, Paula, et al.
Publicado: (2016)

Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2(V617F) myeloproliferative neoplasms
por: Courdy, Charly, et al.
Publicado: (2023)

NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature
por: Catalano, Gianfranco, et al.
Publicado: (2020)

Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
por: Huo, Li, et al.
Publicado: (2023)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic Transplantation
por: Villafuerte-Gutiérrez, Paola, et al.
Publicado: (2018)

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
por: Romagnoli, Simone, et al.
Publicado: (2021)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
por: Eliaçık, Eylem, et al.
Publicado: (2015)

Transforming and Tumorigenic Activity of JAK2 by Fusion to BCR: Molecular Mechanisms of Action of a Novel BCR-JAK2 Tyrosine-Kinase
por: Cuesta-Domínguez, Álvaro, et al.
Publicado: (2012)

Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm
por: Kim, Dong Hyun, et al.
Publicado: (2023)

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
por: Low, Soon Khai, et al.
Publicado: (2022)

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
por: Goker Bagca, Bakiye, et al.
Publicado: (2020)

The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes
por: Griveau, Audrey, et al.
Publicado: (2020)

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
por: Smith, Paul, et al.
Publicado: (2021)

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
por: Marcuzzi, Annalisa, et al.
Publicado: (2022)

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia
por: Oyogoa, Emmanuella, et al.
Publicado: (2023)

Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53
por: Wang, Qian, et al.
Publicado: (2020)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8i7cq33l98hmvh9erjftv4lo40